Recent treatment breakthrough including BRAF/MEK-targeted therapies and immune checkpoint inhibitors (ICIs) have improved survival in advanced melanoma (4–8), but approximately half of patients fail to achieve long-term benefit (8, 9). This evidence concerns the gene BRAF and melanoma.